Out of $700bn in impact investing only 7% goes towards healthcare. But Johnson & Johnson is looking at ways to move the needle.

Sarah Hubar-Fisher Johnson & Johnson

There is an estimated $700bn of impact investing going on, but only 7% of it is being directed at healthcare — so this is an area with a lot of room for improvement. This was the message from Sarah Hubar-Fisher, senior director of Global External Innovation at pharmaceutical firm Johnson & Johnson at the GCV Symposium.

Hubar-Fisher, however, has an idea for how to move…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Kaloyan Andonov

Kaloyan Andonov is head of analytics at Global Corporate Venturing.
email
Linked in